Jaume Capdevila

12.8k total citations · 6 hit papers
128 papers, 8.0k citations indexed

About

Jaume Capdevila is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, Jaume Capdevila has authored 128 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 98 papers in Epidemiology and 69 papers in Neurology. Recurrent topics in Jaume Capdevila's work include Neuroendocrine Tumor Research Advances (98 papers), Lung Cancer Research Studies (87 papers) and Neuroblastoma Research and Treatments (67 papers). Jaume Capdevila is often cited by papers focused on Neuroendocrine Tumor Research Advances (98 papers), Lung Cancer Research Studies (87 papers) and Neuroblastoma Research and Treatments (67 papers). Jaume Capdevila collaborates with scholars based in Spain, United States and United Kingdom. Jaume Capdevila's co-authors include Marianne Pavel, Edward M. Wolin, Kjell Öberg, Guido Rindi, Martyn Caplin, James C. Yao, Eric Van Cutsem, Réza Kianmanesh, Timothy J. Hobday and Elisabeth G.E. de Vries and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Jaume Capdevila

123 papers receiving 7.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

2011 2.1k citations James C. Yao, Manisha H. Shah et al. New England Journal of Medicine profile →
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

2014 1.3k citations Martyn Caplin, Marianne Pavel et al. New England Journal of Medicine profile →
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

2016 911 citations Massimo Falconi, Gregory Kaltsas et al. Neuroendocrinology profile →
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

2016 738 citations Marianne Pavel, Jaume Capdevila et al. Neuroendocrinology profile →
Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

2023 149 citations Jaume Capdevila et al. profile →
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

2024 113 citations Salvatore Tafuto, Jaume Capdevila et al. profile →

Peers

Countries citing papers authored by Jaume Capdevila

Since Specialization

Citations

This map shows the geographic impact of Jaume Capdevila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaume Capdevila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaume Capdevila more than expected).

Fields of papers citing papers by Jaume Capdevila

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaume Capdevila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaume Capdevila. The network helps show where Jaume Capdevila may publish in the future.

Co-authorship network of co-authors of Jaume Capdevila

This figure shows the co-authorship network connecting the top 25 collaborators of Jaume Capdevila. A scholar is included among the top collaborators of Jaume Capdevila based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaume Capdevila. Jaume Capdevila is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer 2025 ·Cell Reports Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Cristina Viaplana, (unknown), Joaquı́n Mateo, (unknown), (unknown), Francesc Salvà, Jaume Capdevila, Elena Élez, (unknown), Elena Garralda, Raquel Pérez-López	3
2	Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial. 2023 ·Journal of Clinical Oncology ·Þorvarður R. Hálfdánarson, Jaume Capdevila, Daniel M. Halperin, Ken Herrmann, Grace Kong, (unknown), Josh Mailman, Diane Reidy‐Lagunes, Rajaventhan Srirajaskanthan, (unknown), (unknown), Thomas Thevenet	0
3	Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module) 2022 ·Journal of Neuroendocrinology ·John Ramage, Elizabeth Friend, (unknown), Barbara King, Paz Fernández‐Ortega, Mairéad G. McNamara, Gregory Kaltsas, Massimo Falconi, (unknown), Jaume Capdevila, Simona Grozinsky‐Glasberg, Dalvinder Mandair, Eva‐Maria Gamper, Raj Srirajaskanthan, Martin O. Weickert, Debra Gray, (unknown)	4
4	Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors 2022 ·Neuroendocrinology ·Jaume Capdevila, Michel Ducreux, Rocio García‐Carbonero, Enrique Grande, Þorvarður R. Hálfdánarson, (unknown), Salvatore Tafuto, Staffan Welin, Vicente Valentí, Ramón Salazar	22
5	Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia 2022 ·Endocrine Reviews ·Rodrigo A. Toledo, Camilo Jiménez, (unknown), (unknown), Jaume Capdevila, Patricia L. M. Dahia	47
6	Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial 2021 ·Clinical Cancer Research ·Joana Vidal, David Casadevall, Beatríz Bellosillo, Carles Pericay, Rocio García‐Carbonero, Ferrán Losa, (unknown), Vicente Alonso, Jaume Capdevila, Javier Gállego, Ruth Vera, Antonieta Salud, Marta Martín-Richard, Miguel Nogué, (unknown), Joan Maurel, Iris Faull, Victoria M. Raymond, Carlos Fernández-Martos, Clara Montagut	62
7	Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT 2021 ·Journal of Clinical Medicine ·Meritxell Mollà, (unknown), Santiago Albiol, Constantino Fondevila, Iván Vollmer, (unknown), Ángeles García‐Criado, Jaume Capdevila, Carles Conill, (unknown), Carlos Fernández-Martos, Estela Pineda	15
8	Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial 2021 ·The Oncologist ·Enrique Grande, Cristina Rodríguez‐Antona, Carlos López, Teresa Alonso‐Gordoa, Marta Benavent, Jaume Capdevila, Àlex Teulé, Ana Custodio, Isabel Sevilla, Jorge Hernando, Pablo Gajate, Javier Molina‐Cerrillo, Juan J. Díez, María Santos, Javier Lanillos, Rocio García‐Carbonero	16
9	The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407) 2020 ·The Oncologist ·Enrique Grande, Àlex Teulé, Teresa Alonso‐Gordoa, Paula Jiménez‐Fonseca, Marta Benavent, Jaume Capdevila, Ana Custodio, Ruth Vera, (unknown), Adelaida La Casta, Juan J. Díez, Pablo Gajate, Javier Molina‐Cerrillo, Ignacio Matos, Eva Cristóbal, J.C. Ruffinelli, José Palacios, Rocio García‐Carbonero	24
10	Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas 2019 ·Clinical Cancer Research ·Jaume Capdevila, Oriol Arqués, José Ramón Hernández Mora, Judit Matito, Ginevra Caratù, Francesco M. Mancuso, Stefania Landolfi, Jorge Barriuso, Paula Jiménez‐Fonseca, Carlos López, Rocio García‐Carbonero, Jorge Hernando, Ignacio Matos, (unknown), Javier Hernández‐Losa, Manel Esteller, Anna Martínez‐Cardús, Josep Tabernero, Ana Vivancos, Héctor G. Pálmer	28
11	VITAL phase 2 study: Upfront 5‐fluorouracil, mitomycin‐C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09‐02) 2019 ·Cancer Medicine ·Jaime Feliú, Rocio García‐Carbonero, Jaume Capdevila, (unknown), (unknown), Carlos López, Pilar García‐Alfonso, (unknown), Isabel Sevilla, L. Cerezo, Carles Conill, (unknown), (unknown), Ismael Ghanem, Marta Martín-Richard, Miriam López-Gómez, Ana León, (unknown), Teresa de Souza Fernandez, Joan Maurel	8
12	SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018) 2018 ·Clinical & Translational Oncology ·Encarnación González‐Flores, Rafael Serrano del Rosal, Isabel Sevilla, A. Viúdez, Jorge Barriuso, Marta Benavent, Jaume Capdevila, (unknown), Carlos López, Rocio García‐Carbonero	13
13	Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours 2018 ·Cancer Treatment Reviews ·Jorge Barriuso, Ana Custodio, (unknown), Vicente Alonso, Aurora Astudillo, Jaume Capdevila, Rocio García‐Carbonero, Enrique Grande, Paula Jiménez‐Fonseca, Mónica Marazuela, Cristina Rodríguez‐Antona, Javier Aller	13
14	Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms 2018 ·Neuroendocrinology ·Robert T. Jensen, Lisa Bodei, Jaume Capdevila, Anne Couvelard, Massimo Falconi, Simona Grozinsky‐Glasberg, Günter Klöppel, Steven W. J. Lamberts, Marc Peeters, Guido Rindi, Anja Rinke, M Rothmund, Anders Sundin, Staffan Welin, Nicola Fazio, (unknown)	42
15	Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension 2017 ·Annals of Oncology ·Jarosław B. Ćwikła, Edward M. Wolin, Marianne Pavel, Alexandria T. Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Jaume Capdevila, Guido Rindi, Catherine Lombard‐Bohas, (unknown), (unknown), Philippe Ruszniewski, Martyn Caplin	2
16	ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation 2017 ·Neuroendocrinology ·Ulrich Knigge, Jaume Capdevila, D.K. Bartsch, Éric Baudin, Jenny Falkerby, Réza Kianmanesh, Beata Kos‐Kudła, Bruno Niederle, Els Nieveen van Dijkum, (unknown), Andreas Pascher, Nick Reed, Anders Sundin, Marie‐Pierre Vullierme, (unknown)	88
17	Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study 2016 ·Journal of Clinical Oncology ·James C. Yao, Marianne Pavel, Catherine Lombard‐Bohas, Eric Van Cutsem, Maurizio Voi, Ulrike Brandt, Wei He, David Chen, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Timothy J. Hobday, Rodney F. Pommier, Kjell Öberg	192
18	Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors breakdown → 2014 ·New England Journal of Medicine ·Martyn Caplin, Marianne Pavel, Jarosław B. Ćwikła, Alexandria T. Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M. Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley, Séverine Martinez, Joëlle Blumberg, Philippe Ruszniewski	1286
19	A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors 2011 ·Clinical Cancer Research ·Josep Tabernero, Luc Dirix, Patrick Schöffski, Andrés Cervantes, José A. López-Martín, Jaume Capdevila, Ludy van Beijsterveldt, Suso Platero, Brett M. Hall, Zhilong Yuan, Roland E. Knoblauch, Sen Hong Zhuang	46
20	Everolimus for Advanced Pancreatic Neuroendocrine Tumors breakdown → 2011 ·New England Journal of Medicine ·James C. Yao, Manisha H. Shah, Tetsuhide Ito, C. Lombard Bohas, Edward M. Wolin, Eric Van Cutsem, Timothy J. Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Marianne Pavel, Sakina Hoosen, T Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg	2078

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact